Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

1.650 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... 
Via Talk Markets
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. 
Via Talk Markets
Atai's Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline's Psilocybin, DMT, Ketamine & MDMA
Atai Life Sciences (NASDAQ: ATAI) reported its consolidated, unaudited financial results for the second quarter 2023 ended June 30. Numbers show: 
Via Benzinga
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
From atai Life Sciences
Via GlobeNewswire
Atai's Clinical Results Of R-Ketamine For Depression: Road To Subcutaneous At-Home Administration
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) shared results from majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of its... 
Via Benzinga
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
From atai Life Sciences
Via GlobeNewswire
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July: 
Via Talk Markets
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug... 
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD
Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD. 
Via Talk Markets
Psychedelic Stocks Jumped 10% Last Week
The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly 
Via Talk Markets
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital
Mental health psychedelics biotech company COMPASS Pathways (NASDAQ: CMPS) received funding for its COMP360 Phase 3 program in Treatment-Resist 
Via Benzinga
Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues
Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up... 
Via Talk Markets
Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue
There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD. 
Via Talk Markets
MAPS' Psychedelic Science 2023: Gov. Polis To Open Event, New Shulgin Compounds To Be Revealed
Psychedelic Science, this year’s gathering hosted by the legendary nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced its final agenda,... 
Via Benzinga
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May. 
Via Talk Markets
atai Life Sciences to Participate in Upcoming June Investor Conferences
From atai Life Sciences
Via GlobeNewswire
3 Penny Stocks to Make You the Millionaire Next Door
Explore the world of high-risk, high-reward top penny stocks to buy and uncover promising investment opportunities. 
Via InvestorPlace
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights. Consolidated... 
Via Benzinga
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in Upcoming May Investor Conference
From atai Life Sciences
Via GlobeNewswire
April Psychedelic Drug Stocks Recap: The Ups And Downs
Via Talk Markets
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
From atai Life Sciences
Via GlobeNewswire
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Invitae, CSX And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gained in today’s pre-market trading session. Mullen Automotive, Inc. (NASDAQ: MULN) shares jumped 30.2% to $0.1103 in... 
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.